Claris Lifesciences, one of the largest sterile injectables pharmaceutical companies in India, has received supplemental abbreviated new drug application (ANDA) approval for Fluconazole Injection in the United States of America (US).

The company currently markets Fluconazole in 2mg/ ml formulation packed in 100ml and 200ml PVC bags and now with the approval of supplemental ANDA, Claris is the only company to be able to sell Fluconazole in 50 ml variant in the US. By launching this variant Claris will be addressing the need of the medical fraternity.

Shares of the company gained Rs 8.6, or 3.13%, to trade at Rs 283.00. The total volume of shares traded was 888,441 at the BSE (1.45 p.m., Tuesday).